Skip to content

Advertisement

Featured article: The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer’s disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we set up the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study. We confirm the central roles of Aβ and APOE ε4 in AD pathogenesis. The results of the multimodal analyses will provide new insights into underlying mechanisms and facilitate the discovery of new diagnostic and prognostic AD biomarkers. 

Read More

Resilience in Dementia Series

New Content Item

Brain resilience is the process of adapting well in the face of significant sources of stress, such as Alzheimer’s disease pathology, other neurodegenerative conditions or biological aging.  This thematic series provides a comprehensive overview of what factors contribute to brain resilience and how this affects brain health and cognitive function.

Read the articles

Guest ​​​​​​​Editor: Rik Ossenkoppele

Publication: Ongoing but closed for submissions


Articles

Most accessed articles RSS

View all articles

Alzheimer's Disease International

Read more about the upcoming conference here.

ADI 2018 is the longest running and most diverse international conference on dementia. The conference will feature leading experts on a range of topics including the latest in dementia science and care, presentations by people with dementia and their care partners, discussions on prevention, diagnosis, engaging minority groups and a unique focus on how technology and innovation is shaping the future.

The Journal Development Editor for the journal will be in attendance from 26th-29th of July. Please email elizabeth.anderson@springernature.com if you would like to meet.

Aims and scope

Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.

Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.

Latest Tweets

Advertisement

Affiliated with

2017 Journal Metrics

Advertisement